1. ABPI and our Regional
Industry Groups
Karen Thomas, Regional Partnership Manager London | ABPI

2. Focus for the day
• The ABPI
• The background to our team
• Regional Industry Group – London
• Hear from our speakers
• Joint working masterclass
• What all this means for you
Further reading
http://www.abpi.org.uk/our-work/news/2012/Pages/140512.aspx

4. Real world data and e-health
ABPI landscape and policy map
Innovation, Health
and Wealth
value
based
pricing
PPRS
Commissioning
Reputation
UK Competitiveness
NHS Partnerships
Discovery Development Approval Fair Price Access Uptake Patients
Supply Chain
Partnerships for research
Animal research
EU Influence
Clinical research
Regulatory framework and MHRA
Manufacturing and the environment
Schools, higher education and skills
Intellectual property and patent
Pharmacovigilance
Patient Group Forum
Medicines Optimisation
HTA

5. IHW - Accelerating adoption and diffusion in the NHS
• Innovation, Health and
Wealth report was
published on 5th December
2011
• Sir David Nicholson also
sent a letter outlining his
expectations for NHS
action
• ABPI warmly welcomed
the report as a
significant step forward
to support adoption and
diffusion of innovative
medicines across the
NHS

6. Our partnerships for delivery
• We have an MOU with the NHS Confederation, ABHI and Medilinks to support the
implementation of Innovation, Health and Wealth
http://www.nhsconfed.org/priorities/latestnews/Pages/NHS-Confederation-joins-
ABPI-ABHI-innovation-project.aspx
• This strategic agreement aims to increase the adoption and diffusion of proven
technologies in areas of high clinical need to deliver high quality patient outcome
and efficiency gains
• It includes showcasing best practice for joint working, judged by an independent
panel – our first launch event was in February
• We work on policy at a national level with a range of organisations, including the
DoH, NHS England, NICE, Royal Colleges and others

7. Both the NHS and pharma have their challenges….
• QIPP Challenge - £20bn in 4 years- and £50bn in future years . “Doing more with
less”
• Care scandals – Mid Staffs, Winterbourne and many others - So quality needs to
dramatically improve while budgets shrink – and we have just had an NHS
reorganisation that‟s “so big, you can see it from space”
• As for pharma – are the days of blockbusters over? R&D is getting harder,
development is often through acquisition and industry is a global business. Other
issues include patent expiry, changing business models, biotech companies – we
work in a rapidly shifting environment

8. Our vision
NHS Partnerships Team established in 2012,
led by Carol Blount, our director:
– Kevin Blakemore, National Manager
– Regional Managers:
– Di Vegh (South)
– Harriet Lewis (North)
– Andy Riley (Mids and East)
– Karen Thomas (London)
– Mike Ringe, Therapy Group Manager
– Terry Harrison, consultant
– Industry secondee
currently Farid Bidgoli from AZ
Industry as an integral part of the NHS’s solution
to the delivery of better patient outcomes

9. NHS Partnership team priorities
We are:
- Identifying and sharing local NHS issues, organisational and policy changes with member
companies
- Taking the lead on themes from the Innovation, Health and Wealth and other key priorities,
e.g. medicines optimisation
- Demonstrating the value of medicines as an opportunity to improve outcomes rather than as
a cost pressure to commissioners and providers
- Supporting companies in the development of Joint Working projects
We aren’t:
- Promoting a particular company/ therapy area or product
- Trying to improve your market share
- Replicating or „competing‟ with member company field teams
- The only way that the NHS can engage with pharma

10. 1. Wide range of transformational skills, knowledge and experience of Pharma and
the new NHS
2. Brokerage to help Pharma and NHS relationships and improve the environment for
business to business interaction and shared learning
3. Identifying opportunities and 'partnerships' that involves a mutually beneficial
transaction between industry, NHS and other potential partners, that in some cases,
an individual company would not be privy to.
4. Understand the barriers to access and what enablers can be used to break these
down to bring parties together
5. Experts in the use of the “7 step partnership model” and how it should be used to
enable openness & transparency
10
The Partnership team’s USP

11. Regional Industry Groups
• Summer 2012, we wrote to all member company GMs, asking for nominations to sit
on our Regional Industry Groups = RIGs
• Individuals had to have at least 5+ years of market access experience at a senior
level, and be prepared to take an industry perspective
• The ABPI funds these groups – they are not „pay to play‟
• Each region was allocated 12 – 15 places and the first meeting took place in the
South in November 2012
• We elected a Chair – Stephen Fensome, Almirall – and a deputy Chair – Nick
Jones
• The ABPI Regional Manager organises all the meetings and provides secretariat

12. Joint working in London ?

13. Quotes on Joint Working
I am appalled when
reps come to see me
and are ill prepared
and don‟t do their
research . All the
information is in the
public domain.
Chief Pharmacist,
secondary care
“JW with
governance –
fantastic! This is
exactly what is
needed.” – Lead
Pharmacist,
primary care
We want industry to get
involved in the projects at
the embryonic stage. We
want a long-term
sustainable relationship.”
- Consultant secondary
care
“I wish this JW criteria
existed before. It makes
the NHS feel safer
working with industry,
especially as the ABPI
is endorsing it.” –
Governance Manager
secondary care
“Why doesn‟t
pharma just provide
sponsorship and let
the NHS do the
rest?” – Primary
Care lead
“I‟m interested in
JW, but what does
industry have to
offer?” –
Innovation Lead
secondary care
“It‟s disappointing
when pharma
provides financial
resources but no
other resource.” –
Governance Manager
secondary care
“The CCGs are
gagging for JW with
industry, but it has to
be open &
transparent.” – Lead
Pharmacist, primary
care
“NHS is wary to
work with pharma,
so you have to sell
the concept of JW.”
– Pharmaceutical
Advisor primary
care

14. Thank you & enjoy your
meeting